We had the pleasure to speak with Coleen Cunningham (Duke University School of Medicine, Durham, NC, US) to discuss the development of VRC07-523LS for the prevention of HIV in infants and children.
The abstract entitled: ‘Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants’ (OA03.02) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.
Coleen Cunningham would like to thank all individuals involved in the study and sites, and would also like to recognize all the parents and children involved in the study for their contribution.
Questions:
- What are the major unmet needs in prevention of HIV in infants and children? (0:11)
- What is the rationale for the administration of broadly neutralizing, monoclonal antibodies (mAb) to HIV-exposed infants? (0:42)
- What is VRC07-523LS and what are its potential advantages compared with other mAbs? (1:44)
- Could you tell us a little about the study you are presenting, and its safety and tolerability findings? (3:15)
- What will be the next steps in the clinical development of VRC07-523LS? (4:23)
Disclosures: Coleen Cunningham has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the HIVR4P 2021 Virtual Meeting.
